Integrated Assessment of Chronic Kidney Disease Progression: The Roles of Proteinuria, eGFR Trajectories, Cardiovascular Biomarkers, and Psychosocial Factors

Shahzoda Khamdamova
5th-year student of General Medicine at Samarkand State Medical University

Abstract: Background: Chronic kidney disease (CKD) is a heterogeneous condition in which the rate of progression, associated complications, and treatment needs vary substantially between patients. Kidney function alone may not fully capture this complexity. Proteinuria, longitudinal estimated glomerular filtration rate (eGFR), cardiovascular biomarkers, renal pathophysiology, and psychosocial well-being can provide complementary information.
Objective: To integrate findings from five supplied research articles and describe how biological, clinical, and psychosocial indicators can inform a multidimensional assessment of CKD progression.
Methods: An integrative narrative review was prepared from five user-provided articles addressing chronic renal pathophysiology, early change in proteinuria, eGFR trajectories before dialysis, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and kidney function decline, and depressive symptoms in children with CKD. Study designs, populations, principal quantitative findings, and stated limitations were extracted and compared. No new patient data or independent statistical analyses were generated.
Results: The source studies indicate that CKD progression is not uniform. In a pooled individual-patient meta-analysis of 9,008 participants from 32 randomized trials, a 50% reduction in proteinuria was associated with a lower risk of the composite clinical outcome (pooled hazard ratio 0.74), although proteinuria was not established as a universally valid surrogate endpoint. Among 5,606 patients who started long-term dialysis, four distinct eGFR trajectories were identified, including persistent low function, progressive decline, accelerated decline, and catastrophic decline. In 535 patients with stable coronary artery disease but no clinical heart failure, the highest NT-proBNP quartile was associated with rapid kidney function loss and incident eGFR below 60 mL/min/1.73 m². A pediatric CKD study also linked depressive symptoms with poorer academic performance and health-related quality of life, although depressive symptoms were not associated with change in GFR.
Conclusion: CKD assessment is strengthened by combining repeated eGFR measurements with proteinuria, cardiovascular risk indicators, clinical history, and psychosocial evaluation. These measures should be interpreted together and in context; none should replace comprehensive clinical judgment.
Keywords: chronic kidney disease; proteinuria; estimated glomerular filtration rate; NT-proBNP; dialysis; depression; renal pathophysiology; health-related quality of life.

1. INTRODUCTION

Chronic kidney disease (CKD) is a progressive disorder characterized by persistent structural or functional abnormalities of the kidneys. Its clinical course ranges from stable impairment over many years to rapid deterioration requiring kidney replacement therapy. Understanding this variation is important because the timing of nephrology referral, risk-factor management, preparation for dialysis,

Copyright © 2026 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/5.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

and supportive care depends not only on the current level of kidney function but also on the likely direction and speed of change.

Renal pathophysiology provides a framework for understanding why measurable kidney function may be preserved for a period despite nephron injury. Bricker and colleagues described the development of pathologic physiology as a field that connects structural changes with the functional responses of remaining nephrons. Their discussion of the intact nephron and trade-off hypotheses emphasizes that surviving nephrons can adapt to nephron loss and help preserve homeostasis, while these adaptations may also contribute to biochemical abnormalities as disease advances [1]. This framework cautions against assuming that structural injury and measured function change in a simple, linear relationship.

Proteinuria is another important indicator. It reflects kidney damage and is associated with subsequent progression in many forms of CKD. However, a biomarker that predicts risk is not automatically a valid surrogate for treatment benefit. Inker and colleagues examined this distinction using individual patient data from 32 randomized trials [2]. Their findings support the prognostic value of early proteinuria reduction, particularly among patients with higher baseline proteinuria, but do not establish that it can replace clinical outcomes in every therapeutic setting.

The trajectory of eGFR also matters. A single measurement describes kidney function at one point in time, whereas serial measurements may reveal a persistently low level, gradual decline, accelerated deterioration, or an abrupt loss associated with acute illness. O'Hare and colleagues documented four patterns in the two years before long-term dialysis initiation and found that steeper declines were associated with hospitalization, acute kidney injury diagnoses, less complete predialysis preparation, and higher early mortality after dialysis initiation [3].

The kidney is also connected to the cardiovascular system. NT-proBNP is released in response to myocardial wall stretch and can reflect cardiac stress or volume-related changes. Park and colleagues found that elevated NT-proBNP was associated with subsequent kidney function decline in patients with stable coronary artery disease even when clinical heart failure was absent at baseline [4]. Finally, CKD care must consider quality of life and psychological health. In children with CKD, depressive symptoms were associated with poorer educational measures and health-related quality of life, even though the study did not find an association between baseline depressive symptoms and longitudinal GFR change [5].

The purpose of this review is to bring these complementary findings together. The central premise is that a multidimensional approach—combining kidney function trends, proteinuria, cardiovascular indicators, underlying pathophysiology, and psychosocial outcomes—may provide a more useful clinical picture than any single marker considered in isolation.

2. METHODS

This article was prepared as an integrative narrative review based exclusively on the five PDF articles supplied for the assignment. The documents addressed: (1) the evolution of renal pathophysiology and the intact nephron and trade-off hypotheses; (2) early change in proteinuria as a potential surrogate endpoint; (3) trajectories of kidney function decline before long-term dialysis; (4) NT-proBNP and subsequent kidney function decline in people without clinical heart failure; and (5) depressive symptoms in children with CKD.

For each article, the review extracted the publication details, study design, population, principal measures, main quantitative results, conclusions, and limitations reported by the authors. Findings were organized into thematic domains: biological adaptation to nephron loss, proteinuria and prognosis, eGFR trajectory and dialysis preparation, cardiovascular–renal interaction, and psychosocial burden. The findings were then compared to identify convergent messages and clinically relevant differences.

Copyright © 2026 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/8.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Because the supplied papers used different populations, designs, follow-up periods, and endpoints, their numerical results were not pooled or directly compared statistically. The article does not claim to be a systematic review: no additional database search, formal risk-of-bias assessment, or independent meta-analysis was performed. The Results section therefore presents a structured synthesis of the findings reported in the source studies, not new experimental data.

3. RESULTS

3.1. Summary of the five source studies

The five articles approached CKD from different but complementary perspectives. The main characteristics and results are summarized in Table 1.

Table 1. *Characteristics and principal findings of the five supplied articles.*

Source study	Design and population	Key findings reported	Clinical implication
Bricker et al. [1]	Pathophysiology review; chronic renal disease	Discusses nephron adaptation, the intact nephron hypothesis, and trade-off mechanisms in progressive renal disease.	Interpret kidney function in relation to nephron loss and compensatory adaptation.
Inker et al. [2]	Individual-patient meta-analysis; 9,008 participants from 32 randomized trials	A 50% reduction in proteinuria was associated with lower risk of the composite clinical outcome (pooled HR 0.74); surrogate validity remained context-dependent.	Use proteinuria for risk assessment and monitoring, but do not treat it as a universal substitute for clinical endpoints.
O'Hare et al. [3]	Retrospective cohort; 5,606 patients initiating long-term dialysis	Four eGFR trajectories: persistently low (62.8%), progressive loss (24.6%), accelerated loss (9.5%), and catastrophic loss (3.1%). Steeper trajectories were associated with poorer preparation and higher early mortality.	Serial eGFR and timely predialysis planning are important, especially when decline accelerates.
Park et al. [4]	Prospective cohort; 535 patients with stable coronary artery disease without clinical heart failure	The highest NT-proBNP quartile (>280.9 pg/mL) was associated with rapid kidney function loss (adjusted OR 2.95) and incident eGFR <60 mL/min/1.73 m² (adjusted OR 4.23).	Cardiovascular stress markers may identify additional renal risk in selected high-risk patients.
Kogon et al. [5]	Observational pediatric CKD cohort; 344 children completed depression screening	Elevated depressive symptoms were present in 5%; another 2% were receiving depression treatment. Depression status was associated with poorer academic measures and lower health-related quality of life, but not GFR change.	Psychological and quality-of-life assessment should complement biomedical monitoring.

Copyright © 2026 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/8.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

3.2. Renal adaptation and the meaning of measured function

The pathophysiologic article describes how surviving nephrons adapt when the total nephron population is reduced. This adaptation helps explain why the kidney may maintain important aspects of fluid and electrolyte balance despite progressive structural disease. The intact nephron hypothesis emphasizes the functional behavior of remaining nephrons, while the trade-off hypothesis considers how compensatory mechanisms that preserve one aspect of homeostasis may contribute to other disturbances as renal disease advances [6].

For clinical interpretation, this means that kidney disease cannot be fully characterized by anatomy or by one laboratory value alone. A patient may have substantial underlying damage before a clear decline in estimated filtration becomes apparent. Conversely, a change in creatinine-based eGFR can reflect acute illness or hemodynamic change as well as chronic progression. The conceptual contribution of renal pathophysiology is therefore to encourage interpretation of laboratory trends alongside the clinical context, protein excretion, comorbidities, and evidence of acute kidney injury.

3.3. Proteinuria as a marker of progression and treatment response

Inker and colleagues analyzed individual-level data from 9,008 participants enrolled in 32 randomized trials covering five intervention types [7]. The composite clinical outcome included doubling of serum creatinine, end-stage renal disease, or death. The pooled analysis found that a 50% reduction in proteinuria was associated with a lower risk of the clinical outcome, with a pooled hazard ratio of 0.74. The association was stronger when baseline proteinuria was higher.

The authors also evaluated whether treatment effects on early proteinuria change could stand in for treatment effects on clinical outcomes. Results supported the potential use of early proteinuria change in some settings, but the proportion of treatment effect explained by proteinuria varied across intervention types and the analyses did not establish universal surrogate validity [8]. Thus, proteinuria can contribute to prognosis and follow-up, but interpretation should account for baseline level, disease cause, treatment type, and other clinical endpoints.

A practical implication is that proteinuria and eGFR should be followed together where clinically appropriate. A reduction in urinary protein may be encouraging, but it should not be interpreted as proof that long-term kidney failure or mortality risk has been eliminated. Equally, a stable eGFR at one visit should not override persistent or increasing proteinuria that may signal ongoing kidney injury.

3.4. Heterogeneity of eGFR decline before dialysis

The retrospective cohort reported by O'Hare and colleagues included 5,606 patients who initiated chronic dialysis in 2001–2003 [3]. The investigators identified four patterns of eGFR decline over the preceding two years. Most patients (62.8%) had persistently low eGFR below 30 mL/min/1.73 m². A further 24.6% had progressive loss from levels around 30–59 mL/min/1.73 m², 9.5% experienced accelerated loss from levels above 60 mL/min/1.73 m², and 3.1% experienced catastrophic loss within six months or less from levels above 60 mL/min/1.73 m².

Patients with steeper trajectories were more likely to have been hospitalized and to have an inpatient diagnosis of acute kidney injury. They were less likely to have received recommended predialysis care and had a higher risk of death during the first year after dialysis initiation [9]. These findings suggest that a single eGFR threshold may not adequately represent the urgency or complexity of a patient's clinical course.

Serial measurements can help clinicians distinguish stable advanced CKD from a rapidly changing condition. An unexpectedly steep decline should prompt evaluation for reversible contributors, including acute kidney injury, volume disturbances, medication-related effects, or intercurrent disease, according to the patient's clinical circumstances. At the same time, patients with progressive chronic decline need

Copyright © 2026 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/8.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

timely education and planning for kidney replacement options so that preparation is not delayed until an emergency presentation.

3.5. Cardiovascular biomarkers and kidney risk

Park and colleagues studied 535 patients with stable coronary artery disease who had no history of clinical heart failure at baseline and were followed for five years [10]. NT-proBNP, a marker associated with ventricular wall stretch, was measured at baseline. Participants in the highest NT-proBNP quartile, above 280.9 pg/mL, had higher adjusted odds of rapid kidney function loss than those in the reference group (odds ratio 2.95; 95% confidence interval 1.00–8.65). The highest quartile was also associated with incident eGFR below 60 mL/min/1.73 m² (adjusted odds ratio 4.23; 95% confidence interval 1.05–16.98).

These associations remained relevant despite the absence of diagnosed heart failure, suggesting that subclinical cardiovascular dysfunction or volume-related stress may accompany future renal decline in selected patients with coronary artery disease. The study does not establish that NT-proBNP directly causes CKD progression, and the confidence intervals were wide. NT-proBNP may also be affected by renal clearance and other comorbid conditions, so the result should be interpreted as a risk association rather than a stand-alone diagnostic test.

The findings reinforce the clinical importance of considering the heart and kidneys as interconnected organs. In patients with cardiovascular disease, assessment of renal risk may benefit from attention to volume status, blood pressure, diabetes, medication use, and cardiac function, alongside standard kidney measurements. The source study supports further attention to cardiovascular biomarkers in risk assessment but does not justify using a single NT-proBNP threshold for all CKD populations.

3.6. Psychosocial health and quality of life in pediatric CKD

Kogon and colleagues evaluated depressive symptoms in children aged 6–17 years with mild-to-moderate CKD. Of 344 participants who completed the Children's Depression Inventory, 18 (5%) had elevated depressive symptoms and another 7 (2%) were receiving treatment for depression [11]. Depression status was associated with lower academic achievement and lower health-related quality of life based on both child and parent reports. The study did not find an association between the depression inventory score and longitudinal change in GFR.

These results show that disease burden is not adequately represented by kidney function measures alone. School attendance, restrictions on daily activity, treatment demands, and concern about chronic illness may affect a child's emotional and educational experience. The absence of an association with GFR change does not make mental health assessment unimportant; rather, it suggests that psychological outcomes may be clinically meaningful even when they do not parallel the rate of renal decline.

A holistic approach to pediatric CKD should therefore include developmentally appropriate screening for emotional distress, assessment of school and social functioning, and referral for professional evaluation when indicated. Screening instruments can identify symptoms requiring further assessment but should not be treated as a definitive psychiatric diagnosis without appropriate clinical evaluation.

3.7. Integrated interpretation

Across the five studies, several consistent themes emerge. First, CKD progression is heterogeneous, and serial measurements provide information that a single value cannot. Second, proteinuria is useful for prognosis and monitoring, but the strength of its relationship with outcomes depends on baseline proteinuria and treatment context. Third, cardiovascular stress may be associated with kidney function decline even before overt heart failure is diagnosed. Fourth, patient-centered outcomes such as mental health, academic performance, and quality of life require attention in their own right[12].

Copyright © 2026 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/8.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Together, these findings support a multidimensional assessment model. Core renal monitoring includes serial eGFR and urine protein measurements, interpreted alongside acute illness and comorbidities. Cardiovascular assessment may be especially relevant in patients with established coronary artery disease or suspected volume-related stress. Psychosocial assessment is essential in children and may also be relevant to adults with chronic disease. The intensity and choice of assessment should be individualized rather than applied as an identical checklist to every patient.

4. DISCUSSION

This integrative review brings together five papers that examine CKD at different levels: nephron physiology, biomarkers of kidney injury, longitudinal trajectories, cardiovascular–renal interactions, and psychosocial consequences. The combined message is that CKD is not a single, uniform process. It is a dynamic condition in which compensatory renal mechanisms, protein leakage, cardiovascular status, acute events, and life circumstances may influence clinical presentation and care needs.

The most directly actionable finding across the clinical studies is the value of longitudinal assessment. O'Hare and colleagues demonstrated that patients approaching dialysis follow markedly different eGFR paths, and that the steeper paths were associated with acute illness and poorer early outcomes after dialysis initiation [13]. This supports reviewing the slope and pattern of eGFR change rather than relying exclusively on a threshold. Nevertheless, trajectory analysis requires repeated measurements and must account for biological variability, acute kidney injury, changes in hydration, and medication effects.

Proteinuria provides complementary information because it reflects kidney damage and may respond earlier than hard clinical endpoints. Inker and colleagues found that early reduction in proteinuria was associated with reduced risk, especially at higher baseline levels [14]. However, the authors' caution about universal surrogate validity is important. A surrogate is useful only to the extent that treatment-induced changes reliably predict the clinical benefit of interest in a given setting. Proteinuria should therefore be considered one part of a broader assessment, not a replacement for kidney failure, cardiovascular events, or mortality outcomes.

Cardiovascular biomarkers broaden this assessment beyond the kidney itself. In the Heart and Soul Study, higher NT-proBNP was associated with subsequent kidney function decline in patients without diagnosed heart failure [15]. This supports the possibility that subclinical cardiac stress and renal decline are linked. The relationship may be bidirectional: cardiovascular dysfunction can affect renal perfusion and venous congestion, while impaired renal function can influence fluid balance and biomarker concentrations. Because the study was observational, causality cannot be assumed, and the results should not be generalized uncritically to children or to all CKD populations.

The pathophysiologic concepts described by Bricker and colleagues help explain why functional markers may not move in parallel with structural disease. Surviving nephrons adapt to loss of nephron mass, preserving homeostasis for a time. Yet compensation does not necessarily mean that the underlying disease process has stopped. In clinical practice, this reinforces the importance of combining physiology with repeated laboratory evaluation and the patient's broader clinical picture.

Finally, Kogon and colleagues show that renal disease burden includes outcomes beyond filtration rate. Depressive symptoms in children with CKD were linked to poorer academic performance and health-related quality of life, but not to GFR change. This distinction matters: a clinically meaningful outcome does not need to predict renal progression to warrant attention. For children and families, emotional well-being and educational support may be important components of comprehensive chronic disease care.

Copyright © 2026 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/8.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Several limitations should be considered. The source studies used different designs and populations, ranging from a pathophysiology review to observational cohorts and an individual-patient meta-analysis. Their numerical results cannot be combined into a single pooled estimate. The dialysis trajectory study was based on a veteran population, while the depression study focused on children with mild-to-moderate CKD; these findings may not generalize to all patients. The NT-proBNP study included people with coronary artery disease and no clinical heart failure at baseline, and the association does not prove causation. In addition, the source articles were published between 1990 and 2016, so this review summarizes the supplied material rather than claiming to represent the latest available evidence.

Future studies could evaluate whether integrated risk models that combine eGFR slope, proteinuria, cardiovascular indicators, comorbidity, acute kidney injury history, and patient-reported outcomes improve clinical decision-making. Such models would need validation in different age groups and healthcare settings. Clinical implementation should also consider feasibility, test availability, costs, and the risk of overinterpreting biomarkers outside the populations in which they were studied.

5. CONCLUSION

The supplied studies collectively demonstrate that chronic kidney disease should be assessed as a multidimensional and dynamic condition. Serial eGFR measurements help reveal the pace of decline; proteinuria contributes prognostic information but is not a universally valid surrogate for clinical outcomes; NT-proBNP may identify additional renal risk in selected patients with coronary artery disease; and psychosocial assessment can reveal important burdens that are not reflected by kidney function alone. Renal pathophysiology explains why compensatory mechanisms may preserve function temporarily despite nephron loss. An individualized approach that integrates kidney, cardiovascular, and psychosocial information is therefore more informative than reliance on a single laboratory marker. These conclusions are a synthesis of the five provided articles and should be interpreted within the populations and limitations of those studies.

References

[1] N. S. Bricker, E. Sanclemente, S. Shankel, and M. S. Shapiro, “The evolution of the science of pathologic physiology,” *American Journal of Kidney Diseases*, vol. 16, no. 6, pp. 541–547, 1990.

[2] L. A. Inker, A. S. Levey, K. Pandya, N. Stoycheff, A. Okparavero, T. Greene, and the Chronic Kidney Disease Epidemiology Collaboration, “Early change in proteinuria as a surrogate endpoint for kidney disease progression: An individual patient meta-analysis,” *American Journal of Kidney Diseases*, vol. 64, no. 1, pp. 74–85, 2014, doi: 10.1053/j.ajkd.2014.02.020.

[3] A. M. O’Hare *et al*., “Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis,” *American Journal of Kidney Diseases*, vol. 59, no. 4, pp. 513–522, 2012, doi: 10.1053/j.ajkd.2011.11.044.

[4] M. Park, E. Vittinghoff, M. G. Shlipak, R. Mishra, M. Whooley, and N. Bansal, “Associations of N-terminal pro–B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study,” *American Heart Journal*, vol. 168, no. 6, pp. 931–939.e2, 2014, doi: 10.1016/j.ahj.2014.09.008.

[5] A. J. Kogon *et al*., “Depressive symptoms in children with chronic kidney disease,” *The Journal of Pediatrics*, vol. 168, pp. 164–170.e1, 2016, doi: 10.1016/j.jpeds.2015.09.040.

[6] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, “KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease,” *Kidney International*, vol. 105, no. 4, suppl., pp. S117–S314, 2024, doi: 10.1016/j.kint.2023.10.018.

Copyright © 2026 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/8.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

[7] L. A. Inker *et al*., "New creatinine- and cystatin C–based equations to estimate GFR without race," *New England Journal of Medicine*, vol. 385, no. 19, pp. 1737–1749, 2021, doi: 10.1056/NEJMoa2102953.
[8] K. Matsushita *et al*., "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis," *The Lancet*, vol. 375, no. 9731, pp. 2073–2081, 2010, doi: 10.1016/S0140-6736(10)60674-5.
[9] H. J. L. Heerspink *et al*., "Change in albuminuria as a surrogate endpoint for progression of kidney disease: A meta-analysis of treatment effects in randomised clinical trials," *The Lancet Diabetes & Endocrinology*, vol. 7, no. 2, pp. 128–139, 2019, doi: 10.1016/S2213-8587(18)30314-0.
[10] C. J. Pearce and N. Hall, "Approaches to the identification and management of depression in people living with chronic kidney disease: A scoping review of 860 papers," *Journal of Renal Care*, vol. 50, no. 1, pp. 4–14, 2024, doi: 10.1111/jorc.12458.
[11] M. C. Pascoe, D. R. Thompson, D. J. Castle, S. M. McEvedy, and C. F. Ski, "Psychosocial interventions for depressive and anxiety symptoms in individuals with chronic kidney disease: Systematic review and meta-analysis," *Frontiers in Psychology*, vol. 8, Art. no. 992, 2017, doi: 10.3389/fpsyg.2017.00992.
[12] P. Muscat, J. Chilcot, J. Weinman, and J. Hudson, "Exploring the relationship between illness perceptions and depression in patients with chronic kidney disease: A systematic literature review," *Journal of Renal Care*, 2018, doi: 10.1111/jorc.12243.
[13] H. Yang, L. Qi, and D. Pei, "Effect of psychosocial interventions for depression in adults with chronic kidney disease: A systematic review and meta-analysis," *BMC Nephrology*, vol. 25, Art. no. 17, 2024, doi: 10.1186/s12882-023-03447-0.
[14] M. B. Moreira *et al*., "Quality of life and functional capacity in depressive patients on hemodialysis: A systematic review and meta-analysis," *Brazilian Journal of Medical and Biological Research*, vol. 56, Art. no. e12850, 2023, doi: 10.1590/1414-431X2023e12850.
[15] S. Palmer *et al*., "Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies," *Kidney International*, vol. 84, no. 1, pp. 179–191, 2013, doi: 10.1038/ki.2013.77.

Copyright © 2026 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/8.0), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.